Other markers that have entered clinical practice include L-FABP, used in Japan to detect AKI in patients with liver failure [9], and NGAL, which is available for use in some European jurisdictions, as dictated by local policies [12]. This evidence concerns the gene FABP1 and acute kidney injury.